Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ

British Journal of Cancer

Volumn 74, Issue 10, 1996, Pages 1578-1585

  Munn, K E ^a   Walker, R A ^b   Menasce, L ^a   Varley, J M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Allelic imbalance; Ductal carcinoma in situ; Immunohistochemistry; Microdissection; TP53

Indexed keywords

PROTEIN P53;

ALLELE; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CARCINOMA IN SITU; CHROMOSOME 17P; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0029956505     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.592     Document Type: Article

References (49)

1. ANDERSEN TI, GAUSTAD A, OTTESTAD L, FARRANTS GW, NESLAND JM, TVEIT KM AND BORRESEN A-L. (1992). Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p and 17q in human breast carcinomas. Genes, Chrom. Cancer, 4, 113-121.
2. ARA S, LEE PSY, HANSEN MF AND SAYA H. (1991). Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res., 18, 4961.
3. BARNES DM, BARTKOVA J, CAMPLEJOHN RS, GULLICK WJ, SMITH PJ AND MILLIS RR. (1992a). Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur. J. Cancer, 28, 644-648.
4. BARNES DM, HANBY AM, GILLET CE, MOHAMMED S, HODGSON S, BOBROW LG, LEIGH IM, PURKIS T, MACGEOCH C, SPURR NK, BARTEK J, VOJTESEK B, PICKSLEY SM AND LANE DP. (1992b). Abnormal expression of wild-type p53 protein in normal cells of a cancer family patient. Lancet, 340, 259-263.
5. BARTEK J, BARTKOVA B, VOJTESEK B, STASKOVA Z, REJTHAR A, KOVARIK J AND LANE DP. (1990). Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int. J. Cancer, 46, 839-844.
6. BETSILL WL, ROSEN PP, LIEBERMAN PH AND ROBBINS GF. (1978). Intraductal carcinoma: long-term follow-up after treatment by biopsy alone. J. Am. Med. Ass., 239, 1863-1867.
7. BOBROW LG, HAPPERFIELD LC, GREGORY WM AND MILLIS RR. (1995). Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J. Pathol., 176, 333-341.
8. CORNELIS RS, VAN VLIET M, VOS CB, CLETON-JANSE A-M, VAN DER VIJVER MJ, PETERSE JL, KHAN PM, BORRESEN A-L, CORNELISSE CJ AND DEVILEE P. (1994). Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumours without p53 mutations. Cancer Res., 54, 4200-4206.
9. DAVIDOFF AM, KERNS B-JM, IGLEHART JD AND MARKS JR. (1991). Maintenance of p53 alterations throughout breast cancer progression. Cancer Res., 51, 2605-2610.
10. DON RH, COX PT, WAINWRIGHT BJ, BAKER K AND MATTICK JS. (1991). 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res., 19, 4008.
11. DUPONT WD AND PAGE DL. (1985). Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med., 312, 146-151.
12. EELES RA, BARTKOVA J, LANE DP AND BARTEK J. (1994). The role of p53 in breast cancer development. Cancer Surveys, 18, 57-75.
13. ELSTON CW AND ELLIS IO. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histapathology, 19, 403-410.
14. FUTREAL AP, BARRETT JC AND WISEMAN RW. (1992). An Alu polymorphism intragenic to the TP53 gene. Nucleic Acids Res., 19, 6977.
15. GUSTERSON BA, MACHIN LG, GULLICK WJ, GIBBS NM, POWLES TJ, ELLIOTT C, ASHLEY S, MONAGHAN P AND HARRISON S. (1988). c-erbB-2 expression in benign and malignant breast disease. Br. J. Cancer, 58, 453-457.
16. GYAPAY G, MORISETTE J, VIGNAL A, DIB C, FIZAMES C, MILLASSEAU C, MARC S, BERNARDI G, LATHROP M AND WEISSENBACH J. (1994). The 1993 1994 Genethon human genetic linkage map. Nature Genet., 7, 246-339.
17. HOLLAND R, PETERSE JL, MILLIS RR, EUSEBI V, FAVERLY D, VAN DER VIJVER MJ AND ZAFRANI B. (1994). Ductal carcinoma in situ: a proposal for a new classification. Semin. Diag. Pathol., 11, 167-180.
18. JONES MH AND NAKAMURA Y. (1992). Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes, Chrom. Cancer, 5, 89-90.
19. LAGIOS MD, WESTDAHL PR, MARGOLIN FR AND ROSE MR. (1983). Duct carcinoma in situ: relationship of extent of noninvasive disease to the frequency of occult invasion, multi-centricity, lymph node metastases and short-term treatment failures. Caner, 50, 1309-1314.
20. MIDGLEY CA, FISHER CJ, BARTEK J, VOJTESEK B, LANE DP AND BARNES DM. (1992). Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J. Cell Sci., 101, 183-189.
21. MOYRET C, THEILLET C, LAURENT P, MOLES J-P, THOMAS G AND HAMELIN R. (1994). Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. Oncogene, 9, 1739-1743.
22. MUNN KE, WALKER RA AND VARLEY JM. (1995). Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast. Oncogene, 10, 1653-1657.
23. MUNN KE, WALKER RA, MENASCE L AND VARLEY JM. (1996). Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast. Br. J. Cancer, 73, 636-640.
24. MURPHY DS, MCHARDY P, COUTTS J, MALLON EA, GEORGE WD, KAYE SB, BROWN R AND KEITH WN. (1995). Interphase cytogenetic analysis of ERBB-2 and TOPOIIa co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int. J. Cancer, 64, 18-26.
25. NOGUCHI S, MOTOMURA K, INAJI H, IMAOKA S AND KOYAMA H. (1994). Clonal analysis of predominantly intraductal carcinoma and precancerous lesions of the breast by means of polymerase chain reaction. Cancer Res., 54, 1849-1853.
26. OLIPHANT AR, WRIGHT EC, SWENSEN J, GRUIS NA, GOLDGAR D AND SKOLNICK MH. (1991). Dinucleotide repeat polymorphism at the D17S513 locus. Nucleic Acid Res., 19, 4794.
27. O'MALLEY FP, VNENCAK-JONES CL, DUPONT WD, PARL F, MANNING S AND PAGE DL. (1994). p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and staining data. Lab. Invest., 71, 67-72.
28. ORITA M, SUZUKI Y, SEKIYA T AND HAYASHI K. (1989). Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5, 874-879.
29. PAGE DL AND ROGERS LW. (1987). Carcinoma in situ (CIS). In Diagnostic Histopathology of the Breast, Page DL and Anderson TJ. (eds) pp. 157-192. Churchill-Livingstone: Edinburgh, UK.
30. PAGE DL, DUPONT WD, ROGERS LW AND LANDENBERGER M. (1982). Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer, 49, 751-758.
31. PAGE DL, DUPONT WD, ROGERS LW AND RADOS MS. (1985). Atypical hyperplastic lesions of the female breast: a long term follow-up study. Cancer. 55, 2698-2708.
32. PAGE DL, DUPONT WD, ROGERS LW, JENSEN RA AND SCHUYLER PA. (1995). Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer, 76, 1197-1200.
33. POLLER DN, ROBERTS EC, BELL JA, ELSTON CW, BLAMEY RW AND ELLIS IO. (1993). p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum. Pathol., 24, 463-468.
34. PROSSER J, THOMPSON AM, CRANSTON G AND EVANS HJ. (1990). Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene, 5, 1573-1579.
35. RADFORD DM, FAIR K, THOMPSON AM, RITTER JH, HOLT M, STEINBRUECK T, WALLACE M, WELLS SA AND DONIS-KELLER HR. (1993). Allelic loss on chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res., 53, 2947-2950.
36. RADFORD DM, FAIR KL, PHILLIPS NJ, RITTER JH, STEINBRUEK T AND HOLT MS. (1995). Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res., 55, 3399-3405.
37. ROSEN PP, BRAUN DW AND KINNE DE. (1980). The clinical significance of preinvasive breast carcinoma. Cancer, 46, 919-925.
38. SHEFFIELD VC, BECK JS, KWITEK AE, SANDSTROM DW AND STONE EM. (1993). The sensitivity of single-strand conformation polymorphism for the detection of single base substitutions. Genomics, 16, 325-332.
39. STACK M, JONES D, WHITE G, LISCIA DS, VENESIO T, CASEY G, CRICHTON D, VARLEY J, MITCHELL E, HEIGHWAY J AND SANTIBANEZ-KOREF M. (1995). Detailed mapping and loss of heterozygosity analysis suggest a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17p13.3. Hum. Mol. Genet., 4, 2047-2055.
40. STRATTON MR, COLLINS N, LAKHANI SR AND SLOANE JP. (1995). Loss of heterozygosity in ductal carcinoma in situ of the breast. J. Pathol., 175, 195-201.
41. TAVASSOLI FA AND NORRIS HJ. (1990). A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer, 65, 518-529.
42. THEILE M, HARTMANN S, SCHERTHAN H, ARNOLD W, DEPPERT W, FREGE R, GLAAB F, HAENSCH W AND SCHERNECK S. (1995). Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes. Hum. Mol. Genet., 10, 439-447.
43. THOR AD, MOORE DH, EDGERTON SM, KAWASAKI ES, REISHAUS E, LYNCH HT, MARCUS JN, SCHWARTZ L, CHEN L-C, MAYALL BH AND SMITH HS. (1992). Accumulation of p53 tumour suppressor gene protein: an independent marker of poor prognosis in breast cancer. J. Natl Cancer Inst., 84, 845-855.
44. VAN DE VIJVER MJ, PETERSE JL, MOOI WJ, WISMAN P, LOMANS J, DALESIO O AND NUSSE R. (1988). neu protein over-expression in breast cancer: association with comedo- type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med., 319, 1239-1245.
45. VARLEY JM, BRAMMAR WJ, LANE DP, SWALLOW JE, DOLAN C AND WALKER RA. (1991). Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene, 6, 413-421.
46. VOJTESEK B, BARTEK J, MIDGELY CA AND LANE DP. (1992). An immunohistochemical analysis of human p53: new monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 151, 237-244.
47. WALKER RA, DEARING S, LANE DP AND VARLEY JM. (1991). Expression of p53 protein in infiltrating and in situ breast carcinomas. J. Pathol., 165, 203-211.
48. WINSHIP PR (1989). An improved method for directly sequencing PCR-amplified material using dimethyl sulphoxide. Nucleic Acids Res., 17, 1266.
49. ZHUANG Z, MERINO MJ, CHUAQUI R, LIOTTA LA AND EMMERTBUCK MR. (1995). Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res., 55, 467-471.